#alzheimers-clinical-trials

[ follow ]
#novo-nordisk #semaglutide #weight-loss-drugs #market-competition
Business
fromFortune
6 hours ago

Novo Nordisk stock trades at 4-year-low on the back of disappointing Alzheimer's trial | Fortune

Novo Nordisk's stock plunged after semaglutide failed Alzheimer's trials, amid slowing weight-loss drug growth, rising competition, regulatory pressure, and risky licensing bets.
[ Load more ]